OncoMatch/Clinical Trials/NCT03739502
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
Is NCT03739502 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Hyperbaric oxygen for aml.
Treatment: Hyperbaric oxygen — The UCB transplant is a type of stem cell transplant used to treat cancer of the blood or lymph glands. The UCB transplant has advantages over other types of transplants such as ease of obtaining the umbilical cord blood, absence of donor risks, reduced risks of contagious infections, and the availability for immediate use. The UCB transplant is also associated with a lower incidence of graft versus host disease, or GvHD (in GvHD, the transplanted graft attacks the recipient organs).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Myelodysplastic Syndrome
Biomarker criteria
Required: BCR BCR-ABL gene positivity
BCR-ABL gene positivity (high-risk ALL feature)
Required: ABL1 BCR-ABL gene positivity
BCR-ABL gene positivity (high-risk ALL feature)
Excluded: NPM1 mutation without FLT3-ITD
NPM1 mutation without FLT3-ITD (favorable risk, excluded from AML CR1 inclusion)
Excluded: FLT3 ITD
NPM1 mutation without FLT3-ITD (favorable risk, excluded from AML CR1 inclusion)
Excluded: CEBPA double-mutated
double-mutated CEBPA (favorable risk, excluded from AML CR1 inclusion)
Demographics
Prior therapy
Must have received: high-dose therapy — relapsed
relapsed following high-dose therapy (HD) [Hodgkin's disease]; relapsed post-high-dose therapy and autologous transplantation [NHL]
Cannot have received: intrathecal chemotherapy
Exception: within 2 weeks of starting preparative regimen
Patients who had intrathecal chemotherapy within 2 weeks of starting preparative regimen
Cannot have received: cranial irradiation
Exception: within 4 weeks of starting preparative regimen
cranial irradiation within 4 weeks of starting preparative regimen
Lab requirements
Kidney function
creatinine: ≤ 1.5 x uln
Liver function
alt, ast: < 4x iuln; total bilirubin: ≤ 2.0 mg/dl
Cardiac function
ef measured by 2d-echo or muga scan of ≥ 45%; ekg with no clinically significant arrhythmia
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Rochester · Rochester, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03739502 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior intrathecal chemotherapy, cranial irradiation disqualifies patients from enrollment.
Does this trial require BCR?
Yes, BCR BCR-ABL gene positivity is a required biomarker for enrollment.
Does this trial require ABL1?
Yes, ABL1 BCR-ABL gene positivity is a required biomarker for enrollment.
Are patients with NPM1 alterations eligible?
No. NPM1 mutation without FLT3-ITD is an exclusion criterion.
Are patients with FLT3 alterations eligible?
No. FLT3 ITD is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify